S u m m a r y
INTRODUCTION
Current technology allows active complexes of substances to be obtained from dry titrated herbal extract (lipophilic-ethanol, hydrophilic-water). They are used as standardized formulations almost utterly devoid of ballast substances in the form of extracts used for the production of oral solid form of a drug [11] .
At present, the most common route of drug administration is oral ingestion. More than 60% of all medicines offered by pharmaceutical industry are administered orally. Tablets are one of the most commonly used drug forms [12] .
Only small number of therapeutic substances are capable of forming tablets under high pressure without the use of excipients. These substances are able to increase plastic deformation and tablet mass liquidity [13] . The Prosolv SMCC 50, PROSOLV EASYtab, EMDEX, Carmellose calcium and PRUV excipients were used in present study as carriers of dry Phaseoli pericarpium extract for direct compression.
To increase the surface area of microcrystalline cellulose for sorption, it can be covered by colloidal silicon dioxide to form silicified microcrystalline cellulose (SMCC). In this case the resulting new excipient was given the trade name Prosolv SMCC 50, and is composed of 98% of microcrystalline cellulose and 2% of colloidal silicon dioxide (SiO 2 ). It has improved binding and disintegrating properties, as well as flowability.
The use of this substance allows the tablets manufacturer by direct compression (excluding the granulation process) to increase the speed of production, to increase tablet hardness and to eliminate the controversial role of excipients, which automatically reduces the tablet size. Furthermore, by decreasing the use of binding substances, the production cost is reduced and thus, the efficacy of tablet compression is increased. It allows for precise distribution of the therapeutically active agent in the manufactured tablet and guarantees the increase of stability of the obtained drug form [14] [15] [16] [17] .
PROSOLV EASYtab is the trade name of an excipient containing 96% microcrystalline cellulose (binder), 2% colloidal silicon dioxide (glidant), 1.3% sodium starch glycolate (disintegrant) and 0.7% sodium stearyl fumarate (lubricant). This substance reduces the content of excipients in tablet manufacture allowing the amount of the therapeutic substance to be increased. Furthermore, the produced tablets are of the same mass, increased hardness and stability and disintegration time is significantly reduced. Prosolv EASYtab is a novel ready-to-use excipient mixture [18] [19] [20] .
EMDEX is the trade mark of a binder used in the production of ingestible, chewable, soluble and effervescent tablets. It consists of 95% glucose, <2% gentobiose, <2% isomaltose, <1% maltose, <0.5% pentose, <0.1% maltotriose. The obtained tablets are characterized by high hardness [19] .
Carmellose calcium, also known as carboxymethylcellulose calcium, and is used in the pharmaceutical industry as a coating agent, disintegrant and stabilizer. It is usually added in amount of 2 to 3% to the tablet mass and acts as a disintegrant in the direct compression process. If a larger amount is used, the disintegration time is prolonged [21] .
Sodium stearyl fumarate (PRUV) is one of the excipients exhibiting gliding, antiadhesive and lubricating properties. It is usually used in the process of tableting at a concentration of 0.5-2%. It is less popular than magnesium stearate, commonly used, but slows tablet disintegration to a lesser degree. It also allows tablets of very good hardness to be produced. Contrary to magnesium stearate, PRUV is a highly water-soluble excipient facilitating flowability, rapid disintegration and preventing tablet crushing [15, 22] . The use of direct compression without granulation is currently gaining popularity in the pharmaceutical industry, because it is simpler and more cost-effective from the point of view of good manufacturing practice (GMP). Hence, new formulations should be designed and the old ones should be modernized, as this will prove to be highly beneficial for many therapeutic substances [23] . The use of dry plant extracts in the process of direct compression without granulation decreases the possible loss of biological activity by the active agents [24] . As dry plant extracts are usually hygroscopic, which creates problems during direct compression, silicon dioxide is applied as a drying adjuvant [25] .
Recently, greater use of tensides (surfactants), particularly non-ionic surfaceactive agents has been observed in the technology of solid oral dosage forms. Surfactants may be used as wetting agents in tablets containing a hydrophobic therapeutic agent, which leads to faster disintegration of the tablet and thus results in better pharmaceutical availability of the active component. The presence of the tenside in the tablet coating accelerates its disintegration.
The aim of this study is to produce a model drug form containing standardized dry Phaseoli pericarpium extract with compatible substances which provide desired tablet disintegration time, appropriate morphological properties and, what is most important, high pharmaceutical availability in model acceptor fluids. By examining the pharmaceutical availability of the substances during the study, our results will indicate the model formulation which will ensure appropriate therapeutic agent release and a high degree of mass exchange at the phase boundary, i.e. the first pass barrier. Non-ionic surfactants will be identified that improve the lithogenic index and at the same time reduce the amount of therapeutic agent adsorbed on the surface of the excipient [26] . Selected surfactants, cholesterol oxyethylenation products (n TE = 30, n TE = 40) and products of oxyethylenation of fatty acid methyl esters contained in pharmacopoeial rapeseed oil (Rofam n TE = 50) [26, 27] were used in the study. Rofams belong to a new class of non-ionic tensides. The parameters given for each surfactant describe the average amount of oxyethylene segments, for instance n TE = 30 indicates the amount of 30. 
MATERIAL AND METHODS

Material
Excipients
The following excipients were obtained from JRS Rettenmaier ( The following homologous series of non-ionic surface-active agents were obtained from the ICSO Blachownia Surface-Active Agents Plant (Kędzierzyn Koźle, Poland): cholesterol oxyethylenation products n TE = 30, HLB = 15.9 [26] , cholesterol oxyethylenation products n TE = 40, HLB = 16.5 [26] , fatty acid methyl ester oxyethylation products of contained in pharmacopoeial rapeseed oil Rofam n TE = 50, HLB = 17.1 [27] .
Reagents
The following reagents were used: water purified according to Eur Ph 7; artificial enzyme-free gastric juice (0.1 mol/l aqueous solution of hydrochloric acid (HCl); artificial enzyme-free intestinal juice (phosphate buffer solution of pH = 6.8). In addition, analytical grade sodium hydroxide and analytical grade potassium dihydrogen phosphate were obtained from POCh, Gliwice, Poland.
Apparatus
Korsch EK-O type reciprocating instrumented tableting machine (Erweka GmbH, Germany); ZT 222 apparatus for testing disintegration rate (Erweka GmbH, Germany); DT 606/1000 HH, apparatus for testing the rate of therapeutic agent release from the drug form (Erweka); TAR 220, friability/abrasion tester (Erweka GmbH, Germany); Nicolet Evolution 300 UV-VIS spectrophotometer, Spectro-Lab (Warszawa, Poland) with PC control and Excel spreadsheet (Microsoft). In addition, the following laboratory equipment was used: a sieve with 0.7 mm mesh diameter, electronic balance, Radwag (Radom, Poland), electronic slide caliper Mitutoyo, Type CD-15CP, Japan.
Technology of model tablet manufacturing
In the first stage, four batches of tablets were manufactured, each tablet containing 50% Phaseoli pericarpium extract (250 mg) with 49% fillers and disintegrants (Prosolv SMCC 50, PROSOLV EASYtab, EMDEX, Carmellose calcium) and 1% PRUV lubricant. In the second stage, an oral solid dosage form was manufactured on the basis of the batch 1 tablet formulation (extract, Prosolv SMCC 50, PRUV) and 1% different surfactants were successively added (cholesterol oxyethylate n TE = 30, cholesterol oxyethylate n TE = 40, Rofam n TE = 50) to obtain three batches of tablets. The composition of individual batches is specified in table 1. All components were weighed per adequate number of tablets (500 mg each). A dry mixing technique was used to produce the tablet mass, and the extract was blended with excipients. The obtained mass was sieved through a 0.7 mm mesh screen, and compressed using a press tablet machine (Erweka) with an Ø11 mm punch. PRUV was used as a lubricant to manufacture all 7 tablet batches: it inhibits the tablet disintegration rate to a lesser extent than magnesium stearate while improving tablet hardness. The manufactured uncoated tablets were tested, and their therapeutic utility was determined.
Morphological tests of tablets with dry extract from Phaseoli pericarpium
The disintegration time of the tablets was determined according to the European Pharmacopoeia 7 [28] . Water, artificial gastric and intestinal juice were used as acceptor fluids.
The tablets were also tested for their appearance (size), dosage accuracy (determination of the mass uniformity of individual tablets) and mechanical resistance (abrasiveness). The hardness of the manufactured tablets was also analysed statistically. The methodology of the study, the size of samples collected for analysis and the limits of acceptable deviation from the expected standard were based on the general and detailed principles of the Eur Ph 7 [28] .
Examination of biologically-active substance content
The actual dose was determined by measuring the active substance content in the tablet. Ten tablets were randomly chosen, weighed and pulverized in a mortar. The resulting powder was prepared for analysis. The corresponding unit weight of the tablet was measured, and the amount of the biologically active substances was determined.
Testing the pharmaceutical availability of active substances from tablet to acceptor fluid
The pharmaceutical availability of biologically active substances from tablets was determined in a dedicated apparatus for measuring therapeutic substance release according to the rotating basket method, in accordance with the Eur Ph 7 [28] . Three types of acceptor fluids were used: water, artificial gastric juice, artificial intestinal juice (enzyme-free, degassed). The dependence of absorbance (A) on concentration function (c) was described with a correlation equation, with a determination coefficient R 2 >0.9990 obtained at a level of significance of p=0.05 (tab. 2). The concentration of the released biologically active substances from the obtained tablets to acceptor fluid was determined using a UV spectrophotometer (l=268 nm) at a temperature of 37±0.5 o C. The sample volume was 10 ml. The acceptor phase consisted of purified water, artificial gastric juice, or artificial intestinal juice. Tablets manufactured only from excipients were used as a reference material. Calibration curves were constructed to quantify the dissolution and diffusion of the sum of biologically active substances to the model acceptor fluids. The results were analysed with the use of Microsoft Excel spreadsheet. Ethical approval: The conducted research is not related to either human or animal use.
RESULTS AND DISCUSSION
Assessment of the quality of tablets containing dry Phaseoli pericarpium extract
The physicochemical properties of the tablets are specified in table 3.
As carriers of dry Phaseoli pericarpium extract, the applied excipients were found to supplement the process of direct tableting. The tablets manufactured within each of seven batches demonstrated a smooth surface with no stains, a uniform shape and yellow color originating from the extract. Low values of deviation from the mean mass (tab. 3) indicated high uniformity of tablet mass. No chips or mechanical defects were present, which was confirmed by testing the mechanical resistance to abrasion: the loss of total mass did not exceed 1%. The abrasiveness oscillated from 0.03 to 0.40%. The highest abrasiveness values were found in the tablets incorporating Carmellose calcium and PRUV (batch 4). The tablets may be considered sufficiently resistant to crushing because the hardness coefficient T was greater than 98 N/cm 2 for all 7 batches of tablets. The hardness of the designed tablets ranged from 119.5 to 268.3 N/cm 2 . The greatest hardness was observed for batch 1B, which contained Prosolv SMCC 50, Oxyethylate n TE = 40 and PRUV. Furthermore, these tablets demonstrated low abrasiveness of 0.07%. The lowest hardness of 119.5 N/cm 2 was noted for batch 4 tablets, which, as it was noted above, were also characterized by the highest abrasiveness (0.4%).
The similar tablet density values observed in all batches confirm that the substances used for tablet manufacturing are homogeneous. This is also confirmed by the calculated mean tablet surface values (tab. 3). Minimal differences were found between the diameter of the tablets from individual batches and the diameter of the punch points to low tension in the tablet pulled out of the matrix. The combination of high hardness values and low abrasiveness (predisposition to crushing) indicates that the tablets can be easily packed into blisters. This formulation ensures morphological durability as the tablet is pulled out from the blister niche.
Ta b l e 3 Tablet physicochemical properties
The process of disintegration was uniform for tablets from all seven batches, with the disintegration time ranging between 6 and 23 minutes. In general, batch 3 tablets (EMDEX, PRUV, Phaseoli pericarpium) demonstrated the shortest disintegration time to all three normative acceptor fluids, the shortest of which was to water (6 min) followed by artificial intestinal juice (7 min) and artificial gastric juice (8 min). The addition of surfactants to the tablets (hydrophilizing agents HLB=15-17) slightly increased their hardness as compared to that of the batch 1 tablets without surfactants. However, this change did not affect the disintegration time of the tablets, which was comparable to that of the batch 1 tablets. This could have been caused by the low ability of substances used for tablet manufacture to reduce the surface tension and phase boundary tension.
The rate of active substance release
The pharmaceutical availability of the biologically active substances from the tested tablets was determined according to the requirements of the Eur Ph 7 [28] . Three types of acceptor fluids recommended by Pharmacopeia were used: water, artificial gastric juice and artificial intestinal juice.
In figure 1 the effectiveness of the release of biologically active substances from individual tablet batches to the acceptor fluid (water) was compared. Batch 4 tablets containing Carmellose calcium as a dominant carrier released the least biologically active substances, obtaining a maximum of 87.2% after 30 min. The release of active substance from batch 2 tables, containing PROSOLV EASYtab, was worse than that of batch 4 tablets: a slow increase of active substance release could be observed in 60 min. The maximum release value was 102.4% after 240 minutes. Batch 3 tablets, containing EMDEX, initially released biologically active substances in a similar way to batch 2 tablets, obtaining a maximum value of 77% after 90 minutes. Further stabilization was observed and then release was slightly decreased. In the case of batch 1 tablets, Prosolv SMCC 50 was used as a main carrier of Phaseoli pericarpium extract. At the beginning of the process of release, this batch exhibited the least pharmaceutical availability: the maximum value of the released active substances, being 75.2% after 150 minutes ( fig. 1 ). This batch of tablets also demonstrated the lowest release to artificial gastric juice (83.6%, fig. 2 ), and to artificial intestinal juice (70.8%, fig. 3 ), as compared to other tablet batches produced during the first stage of the study.
Therefore, to improve pharmaceutical availability, three tablet batches (1A, 1B, 1C) were produced on the basis of the batch 1 tablets (dry Phaseoli pericarpium extract, Prosolv SMCC 50, PRUV by adding successively different surfactants (cholesterol oxyethylate n TE =30, cholesterol oxyethylate n TE =40, Rofam n TE =50). The introduction of 1% of surfactants (batch 1A, 1B, 1C) resulted in a slight increase of pharmaceutical availability to water at the beginning of the process of active substance release compared to batch 1 tablets. Profiles of the release of biologically active substances from tablets to water (batch 1-4, 1A, 1B, 1C)
Figures 2 and 3 specifies the profiles of biologically active substance release from batch 1 tablets to artificial gastric juice and artificial intestinal juice. The release of biologically active substances from batch 1A, 1B and 1C tablets to artificial gastric juice or to artificial intestinal juice was found to be significantly greater than that demonstrated by batch 1 at the beginning of the release process. For the artificial gastric juice, the maximum quantity of the released active substances was 88.4% for batch 1B, containing cholesterol oxyethylate n TE = 40, 88.8% for batch 1A with cholesterol oxyethylate n TE =30, and 89.6% for batch 1C with Rofam n TE =50. These values were higher than that of the batch 1 tablets (83.6%). The maximum release of therapeutic substances to artificial intestinal juice was 78.8% for batch 1A, 78.8% for batch 1C, 99.2% for batch 1B. These values were also higher than those observed for batch 1 tablets, for which the maximum pharmaceutical availability to artificial intestinal juice was 76.8%. Profiles of the release of biologically active substances from tablets to artificial gastric juice (batch 1-4, 1A, 1B, 1C)
It was also indicated that batch 4 tablets, including Carmellose calcium in their composition, released most of their biologically active substances into the external compartment (water, artificial gastric juice and artificial intestinal juice). This batch released the substances slower, i.e. 30 min after other batches.
Despite lacking surfactants, batch 2 tablets containing PROSOLV EASYtab, an innovative mixture of ready-to-use excipients, released the highest amount of biologically active substances to water and artificial intestinal juice, however, in longer time.
The release curve profiles indicated the incomplete release of biologically active substances (i.e. less than 100%). This confirms that sorption of active substances by formulation components was taking place. Summing up, it can be stated that the presented method of manufacturing a solid dosage containing dry Phaseoli pericarpium extract is optimal, ensures technological repeatability and high durability of suggested form. The method of direct compression is cost-and time-effective, as compared to wet granulation.
The obtained tablets can act as supplements for medications for kidney, urinary tract and urinary bladder diseases, as well as in diabetes. The recommended dosage may be 1 tablet containing 250 g of dry extract of Phaseoli pericarpium 3 to 4 times daily. Tabletki wszystkich 7 serii wykonano w tabletkarce uderzeniowej firmy Erweka. Następnie poddano je badaniom morfologicznym, ocenie właściwości fizykochemicznych, a także zbadano profile uwalniania substancji biologicznie czynnych do 3 wybranych płynów biorczych (woda, sztuczny sok żołądkowy, sztuczny sok jelitowy) zgodnie z wymogami przepisów ogólnych i szczegółowych monografii Farmakopei Europejskiej 7 (Eur Ph 7). wyniki: Otrzymane tabletki miały gładką, jednolitą powierzchnię bez plam, odprysków i uszkodzeń mechanicznych. Charakteryzowały się żółtym kolorem pochodzących z ekstraktu. Tabletki posiadające w swoim składzie surfaktanty odznaczały się nieznacznie lepszą dostępnością farmaceutyczną w stosunku do tabletek serii 1 bez surfaktantów. wnioski: Zastosowane substancje pomocnicze w odpowiednich proporcjach okazały się przydatne do wytworzenia tabletek niepowlekanych, zawierających wyciąg z owocni fasoli zwyczajnej.
CONCLUSIONS
Słowa kluczowe: Phaseolus vulgaris, bezpośrednie tabletkowanie, surfaktanty, substancje pomocnicze
